Association of CAG Repeats With Long-term Progression in Huntington Disease.

Langbehn DR, Stout JC, Gregory S, Mills JA, Durr A, Leavitt BR, Roos RAC, Long JD, Owen G, Johnson HJ, Borowsky B, Craufurd D, Reilmann R, Landwehrmeyer GB, Scahill RI, Tabrizi SJ; TRACK-HD and Track-

JAMA Neurol. 2019 Aug 12. doi: 10.1001/jamaneurol.2019.2368. [Epub ahead of print]

Optimization of Potent and Selective Ataxia Telangiectasia-Mutated Inhibitors Suitable for a Proof-of-Concept Study in Huntington's Disease Models.

Toledo-Sherman L, Breccia P, Cachope R, Bate JR, Angulo-Herrera I, Wishart G, Matthews KL, Martin SL, Cox HC, McAllister G, Penrose SD, Vater H, Esmieu W, Van de Poël A, Van de Bospoort R, Strijbosch

J Med Chem. 2019 Mar 28;62(6):2988-3008. doi: 10.1021/acs.jmedchem.8b01819. Epub 2019 Mar 19.

The choice not to undergo genetic testing for Huntington disease: Results from the PHAROS study.

Anderson KE, Eberly S, Marder KS, Oakes D, Kayson E, Young A, Shoulson I; PHAROS Investigators..

Clin Genet. 2019 May 15. doi: 10.1111/cge.13529. [Epub ahead of print]

Brain compensation during visuospatial working memory in premanifest Huntington's disease.

Soloveva MV, Jamadar SD, Velakoulis D, Poudel G, Georgiou-Karistianis N.

Neuropsychologia. 2019 Nov 14;136:107262. doi: 10.1016/j.neuropsychologia.2019.107262. [Epub ahead of print]

Lack of mutant huntingtin in cortical efferents improves behavioral inflexibility and corticostriatal dynamics in Huntington's disease mice.

Estrada-Sánchez AM, Blake CL, Barton SJ, Howe AG, Rebec GV.

J Neurophysiol. 2019 Dec 1;122(6):2621-2629. doi: 10.1152/jn.00777.2018. Epub 2019 Nov 6.

Efficacy of Cholesterol Nose-to-Brain Delivery for Brain Targeting in Huntington's Disease.

Passoni A, Favagrossa M, Colombo L, Bagnati R, Gobbi M, Diomede L, Birolini G, Di Paolo E, Valenza M, Cattaneo E, Salmona M.

ACS Chem Neurosci. 2020 Feb 5;11(3):367-372. doi: 10.1021/acschemneuro.9b00581. Epub 2020 Jan 7.

Olfactory bulb atrophy and caspase activation observed in the BACHD rat models of Huntington disease.

Lessard-Beaudoin M, Yu-Taeger L, Laroche M, Singer E, Riess O, Nguyen HHP, Graham RK.

Neurobiol Dis. 2019 Feb 6;125:219-231. doi: 10.1016/j.nbd.2019.02.002. [Epub ahead of print]

Spatiotemporal gait characteristics of Huntington's disease during dual-task walking.

Radovanović S, Vodopić S, Stanković I, Dragašević-Mišković N, Kostić V.

Int J Neurosci. 2019 Oct 2:1-8. doi: 10.1080/00207454.2019.1667781. [Epub ahead of print]

Stem cells in animal models of Huntington disease: A systematic review.

Colpo GD, Stimming EF, Teixeira AL.

Mol Cell Neurosci. 2019 Jan 24. pii: S1044-7431(18)30391-9. doi: 10.1016/j.mcn.2019.01.006. [Epub ahead of print] Review.

Corrigendum to Restless legs syndrome in NKX2-1-related chorea: An expansion of the disease spectrum" [Brain Dev. 41 (2019) 250-256]."

Iodice A, Carecchio M, Zorzi G, Garavaglia B, Spagnoli C, Salerno GG, Frattini D, Mencacci NE, Invernizzi F, Veneziano L, Mantuano E, Angriman M, Fusco C.

Brain Dev. 2019 Aug;41(7):643. doi: 10.1016/j.braindev.2019.04.011. Epub 2019 Apr 30. No abstract available.

Erucic acid, a nutritional PPARδ-ligand may influence Huntington's disease pathogenesis.

Altinoz MA, Ozpinar A, Ozpinar A, Hacker E.

Metab Brain Dis. 2020 Jan;35(1):1-9. doi: 10.1007/s11011-019-00500-6. Epub 2019 Oct 17. Review.

Laquinimod Treatment Improves Myelination Deficits at the Transcriptional and Ultrastructural Levels in the YAC128 Mouse Model of Huntington Disease.

Garcia-Miralles M, Yusof NABM, Tan JY, Radulescu CI, Sidik H, Tan LJ, Belinson H, Zach N, Hayden MR, Pouladi MA.

Mol Neurobiol. 2019 Jun;56(6):4464-4478. doi: 10.1007/s12035-018-1393-1. Epub 2018 Oct 17.

Targeting Huntingtin Expression in Patients with Huntington's Disease.

Tabrizi SJ, Leavitt BR, Landwehrmeyer GB, Wild EJ, Saft C, Barker RA, Blair NF, Craufurd D, Priller J, Rickards H, Rosser A, Kordasiewicz HB, Czech C, Swayze EE, Norris DA, Baumann T, Gerlach I, Schob

N Engl J Med. 2019 May 6. doi: 10.1056/NEJMoa1900907. [Epub ahead of print]

Microglial depletion prevents extracellular matrix changes and striatal volume reduction in a model of Huntington's disease.

Crapser JD, Ochaba J, Soni N, Reidling JC, Thompson LM, Green KN.

Brain. 2019 Dec 17. pii: awz363. doi: 10.1093/brain/awz363. [Epub ahead of print]

Induced pluripotent stem cells from Huntington's disease patients: a promising approach to define and correct disease-related alterations.

Fatima A, Gutiérrez-Garcia R, Vilchez D.

Neural Regen Res. 2019 May;14(5):769-770. doi: 10.4103/1673-5374.249223. No abstract available.